Expression_NN
of_IN
A-myb_NN
,_,
but_CC
not_RB
c-myb_NN
and_CC
B-myb_NN
,_,
is_VBZ
restricted_JJ
to_TO
Burkitt_NN
's_POS
lymphoma_NN
,_,
sIg_NN
+_CC
B-acute_JJ
lymphoblastic_JJ
leukemia_NN
,_,
and_CC
a_DT
subset_NN
of_IN
chronic_JJ
lymphocytic_JJ
leukemias_NNS
._.

The_DT
A-myb_NN
gene_NN
encodes_VBZ
a_DT
transcription_NN
factor_NN
that_WDT
is_VBZ
related_JJ
both_CC
functionally_RB
and_CC
structurally_RB
to_TO
the_DT
v-myb_NN
oncogene_NN
._.

Following_VBG
our_PRP$
observations_NNS
that_IN
A-myb_NN
is_VBZ
expressed_VBN
in_IN
a_DT
restricted_JJ
subset_NN
of_IN
normal_JJ
mature_JJ
human_JJ
B_NN
lymphocytes_NNS
,_,
with_IN
the_DT
phenotype_NN
CD38_NN
+_NN
,_,
CD39_NN
-_:
,_,
slgM_NN
-_:
,_,
we_PRP
have_VBP
now_RB
investigated_VBN
the_DT
pattern_NN
of_IN
A-myb_NN
expression_NN
in_IN
neoplastic_JJ
B_NN
cells_NNS
representating_VBG
the_DT
whole_JJ
spectrum_NN
of_IN
B-cell_NN
differentiation_NN
and_CC
compared_VBD
it_PRP
to_TO
that_DT
of_IN
c-myb_NN
and_CC
B-myb_NN
._.

In_IN
a_DT
panel_NN
of_IN
32_CD
B-cell_NN
lines_NNS
,_,
A-myb_NN
was_VBD
very_RB
strongly_RB
expressed_VBN
in_IN
most_JJS
Burkitt_NN
's_POS
lymphoma_NN
-LRB-_-LRB-
BL_NN
-RRB-_-RRB-
cell_NN
lines_NNS
,_,
but_CC
weak_JJ
or_CC
negative_JJ
in_IN
2_CD
pre-B_JJ
acute_JJ
lymphoblastic_JJ
leukemia_NN
-LRB-_-LRB-
ALL_NN
-RRB-_-RRB-
,_,
4_CD
non-Hodgkin_JJ
's_POS
lymphoma_NN
-LRB-_-LRB-
NHL_NN
-RRB-_-RRB-
,_,
6_CD
Epstein-Barr_JJ
virus-immortalized_JJ
lymphoblastoid_JJ
cell_NN
lines_NNS
,_,
and_CC
6_CD
myeloma_NN
lines_NNS
._.

Protein_NN
expression_NN
paralleled_VBD
that_DT
of_IN
the_DT
RNA_NN
._.

We_PRP
have_VBP
also_RB
investigated_VBN
A-myb_NN
expression_NN
in_IN
49_CD
fresh_JJ
cases_NNS
of_IN
B_NN
leukemias_NNS
._.

Among_IN
24_CD
ALL_NN
,_,
6_CD
were_VBD
of_IN
the_DT
null_NN
and_CC
11_CD
of_IN
the_DT
common_JJ
type_NN
and_CC
all_DT
these_DT
were_VBD
negative_JJ
for_IN
A-myb_NN
expression_NN
;_:
on_IN
the_DT
other_JJ
hand_NN
,_,
all_DT
7_CD
B-ALL_NN
cases_NNS
-LRB-_-LRB-
slg_NN
+_NN
-RRB-_-RRB-
,_,
as_RB
well_RB
as_IN
one_CD
fresh_JJ
BL_NN
case_NN
with_IN
bone_NN
marrow_NN
infiltration_NN
,_,
expressed_VBD
A-myb_NN
._.

A-myb_NN
was_VBD
undetectable_JJ
in_IN
4_CD
prolymphocytic_JJ
leukemias_NNS
-LRB-_-LRB-
PLL_NN
-RRB-_-RRB-
but_CC
was_VBD
strongly_RB
expressed_VBN
in_IN
5\/20_CD
-LRB-_-LRB-
25_CD
%_NN
-RRB-_-RRB-
of_IN
chronic_JJ
lymphocytic_JJ
leukemia_NN
-LRB-_-LRB-
CLL_NN
-RRB-_-RRB-
samples_NNS
._.

In_IN
the_DT
latter_JJ
A-myb_NN
did_VBD
not_RB
correlate_VB
with_IN
phenotype_NN
or_CC
clinical_JJ
stage_NN
._.

Finally_RB
,_,
we_PRP
have_VBP
studied_VBN
the_DT
progression_NN
of_IN
one_CD
case_NN
of_IN
CLL_NN
into_IN
Richter_NN
's_POS
syndrome_NN
and_CC
have_VBP
found_VBN
that_IN
the_DT
Richter_NN
's_POS
cells_NNS
expressed_VBD
about_RB
25-fold_RB
less_JJR
A-myb_NN
RNA_NN
than_IN
the_DT
CLL_NN
cells_NNS
from_IN
the_DT
same_JJ
patient_NN
._.

The_DT
pattern_NN
of_IN
c-myb_NN
and_CC
B-myb_NN
was_VBD
clearly_RB
distinct_JJ
from_IN
that_DT
of_IN
A-myb_NN
._.

C-myb_NN
and_CC
B-myb_NN
were_VBD
expressed_VBN
in_IN
all_DT
neoplastic_JJ
groups_NNS
,_,
except_IN
in_IN
CLL_NN
cells_NNS
._.

Thus_RB
,_,
A-myb_NN
expression_NN
,_,
unlike_IN
that_DT
of_IN
c-myb_NN
and_CC
B-myb_NN
,_,
is_VBZ
restricted_JJ
to_TO
a_DT
subset_NN
of_IN
B-cell_NN
neoplasias_NNS
-LRB-_-LRB-
in_IN
particular_JJ
BL_NN
and_CC
slg_NN
+_CC
B-ALL_NN
-RRB-_-RRB-
representative_NN
of_IN
a_DT
specific_JJ
stage_NN
of_IN
B-cell_NN
differentiation_NN
._.

This_DT
expression_NN
may_MD
in_IN
part_NN
reflect_VB
expression_NN
of_IN
A-myb_NN
by_IN
the_DT
normal_JJ
germinal_JJ
center_NN
B_NN
cells_NNS
that_WDT
are_VBP
the_DT
normal_JJ
counterpart_NN
of_IN
these_DT
transformed_VBN
B_NN
cells_NNS
._.

The_DT
data_NNS
presented_VBN
strongly_RB
support_VBP
a_DT
role_NN
for_IN
this_DT
transcription_NN
factor_NN
in_IN
B-cell_NN
differentiation_NN
and_CC
perhaps_RB
in_IN
B-cell_NN
transformation_NN
in_IN
some_DT
neoplasias_NNS
._.

